Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...